Ashoka Buildcon shares gain 5% on winning projects worth Rs 2309.99 crore

Ashoka Buildcon Share Price | The share touched a 52-week high of Rs 284.75 and a 52-week low of Rs 120.90 on 06 September, 2024 and 26 October, 2023, respectively.

Moneycontrol News

October 14, 2024 / 09:40 IST

Ashoka Buildcon

live

bselive
nselive

Volume

Todays L/H

Ashoka Buildcon share price rose 5 percent in the early trade on October 14 after the company received Letter of Acceptance (LoA) for two project from Maharashtra State Road Development Corp. Ltd. (MSRDCL).

At 09:34am, Ashoka Buildcon was quoting at Rs 265.65, up Rs 13.85, or 5.50 percent, on the BSE.

The company received engineering, procurement and construction (EPC work) of Rs 310 crore for construction of major bridge across Bankot Creek between Kolmandla, District Raigad to Veshvi on Revas Reddi Costal Highway No. 5 in Ratnagiri District in state of Maharashtra’.

The project is to be executed in 36 months including monsoon.

The company bagged another project from MSRDCL worth Rs 1,999.99 crore for construction of major bridge across Jaigad Creek between Tawsal and Jaigad and construction of major bridge across Kundalika Creek between Revdanda to Salav on Revas Reddi Coastal Highway in Ratnagiri District in the state of Maharashtra.

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show